BioAge Labs (NASDAQ:BIOA) Releases Earnings Results, Beats Estimates By $0.07 EPS

BioAge Labs (NASDAQ:BIOA) announced its earnings results on Wednesday. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.07, Zacks reports. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.

BioAge Labs Stock Performance

BIOA traded down $0.22 during mid-day trading on Wednesday, reaching $10.98. The stock had a trading volume of 1,127,982 shares, compared to its average volume of 713,051. The firm’s fifty day simple moving average is $20.39 and its two-hundred day simple moving average is $19.37. The stock has a market capitalization of $488.09 million, a P/E ratio of -4.57 and a beta of 0.94. BioAge Labs has a 52 week low of $4.25 and a 52 week high of $25.95.

Analysts Set New Price Targets

Several equities analysts have issued reports on BIOA shares. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research report on Friday, July 31st. Needham & Company LLC decreased their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.57.

Hedge Funds Weigh In On BioAge Labs

Several large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its holdings in BioAge Labs by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock valued at $196,000 after acquiring an additional 2,917 shares during the last quarter. Barclays PLC raised its holdings in BioAge Labs by 9.3% during the 4th quarter. Barclays PLC now owns 37,780 shares of the company’s stock worth $500,000 after purchasing an additional 3,222 shares during the last quarter. Bank of America Corp DE lifted its position in BioAge Labs by 46.3% during the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares during the period. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs in the 3rd quarter valued at about $27,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.